UK markets closed

NIKKEI 225
38,460.08
+907.92(+2.42%)
HANG SENG
17,201.27
+372.34(+2.21%)
CRUDE OIL
82.59
-0.77(-0.92%)
GOLD FUTURES
2,335.80
-6.30(-0.27%)
DOW
38,526.11
+22.42(+0.06%)
Bitcoin GBP
52,077.76
-1,540.57(-2.87%)

The five essential pieces of financial paperwork you must never lose

Mislaying key documents can cause real headaches, so it’s worth tracking down these most commonly-lost bits of paperwork

Exicure, Inc. (XCUR)

NasdaqCM - NasdaqCM Real-time price. Currency in USD

Add to watchlist

0.5356

-0.0047

(-0.87%)

As of 12:06PM EDT. Market open.

Trade prices are not sourced from all markets

All

Business Wire
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K
CHICAGO, April 22, 2024--Exicure, Inc. ("Exicure" or the "Company") (Nasdaq: XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC ("Nasdaq") on April 17, 2024 notifying the Company that, as a result of the Company’s failure to timely file its Annual Report on Form 10-K for the year ended December 31, 2023 (the "Form 10-K"), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule"), which requires listed companies to timely file all pe
Business Wire
Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis
CHICAGO, February 05, 2024--Exicure, Inc., (NASDAQ:XCUR) a company that historically developed nucleic acid therapies, and Bluejay Therapeutics, Inc., a private clinical stage biopharmaceutical company focused on viral and liver diseases, announced today that Bluejay Therapeutics, Inc. ("Bluejay") and Exicure, Inc. ("Exicure") entered into a patent license agreement to develop cavrotolimod for potential treatment for hepatitis.
Simply Wall St.
Lacklustre Performance Is Driving Exicure, Inc.'s (NASDAQ:XCUR) 25% Price Drop
Exicure, Inc. ( NASDAQ:XCUR ) shares have had a horrible month, losing 25% after a relatively good period beforehand...